Tandem Diabetes (TNDM) Misses Q1 EPS by 16c

Tandem Diabetes (NASDAQ: TNDM) reported Q1 EPS of ($0.23), $0.16 worse than the analyst estimate of ($0.07). Revenue for the quarter came in at $175.9 million versus the consensus estimate of $168.43 million.

GUIDANCE:

Tandem Diabetes sees FY2022 revenue of $850-865 million, versus the consensus of $846.5 million.

For earnings history and earnings-related data on Tandem Diabetes (TNDM) click here.

You May Also Be Interested In

• Deutsche Bank Starts Tandem Diabetes Care (TNDM) at Hold
• Carnival Corp. (CCL) Tops Q2 EPS by 8c, Beats on Revenue; Offers Guidance
• Bernstein SocGen Group Reiterates Outperform Rating on Hermes International (RMS:FP) (HESAY) after cautious commentary